282 related articles for article (PubMed ID: 27888620)
1. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
2. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
3. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
[TBL] [Abstract][Full Text] [Related]
5. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
7. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
[TBL] [Abstract][Full Text] [Related]
8. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
[TBL] [Abstract][Full Text] [Related]
9. [Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L.].
Soto Parra HJ; Noto L; Aiello MM
Recenti Prog Med; 2020 Dec; 111(12):58e-62e. PubMed ID: 33362184
[TBL] [Abstract][Full Text] [Related]
10. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
11. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
12. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
[TBL] [Abstract][Full Text] [Related]
13. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
15. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
[TBL] [Abstract][Full Text] [Related]
16. Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
[TBL] [Abstract][Full Text] [Related]
17. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
[TBL] [Abstract][Full Text] [Related]
18. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
[TBL] [Abstract][Full Text] [Related]
20. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
